New York, New York (PRWEB) February 25, 2014
As Tylenol lawsuits (http://www.tylenollawsuitclaims.com/ ) continue to move forward in federal court, Bernstein Liebhard LLP notes the publication of a new study which suggests that children who are exposed to acetaminophen in utero may be more likely to develop ADHD. The study, which was published on February 24th in JAMA Pediatrics, reported that children born to women who took the drug during pregnancy were about 40% more likely to be diagnosed with ADHD compared to those whose mothers took none. The probability that a child would develop ADHD symptoms severe enough to warrant medication rose by 62% if their mother used acetaminophen during the second and third trimesters. Women who took acetaminophen during the second trimester only faced a 28% higher risk of having a child with ADHD, while those who only used the medication in their first trimester were 9% more likely to have a child with ADHD.*
“Dozens of lawsuits are currently pending in federal court that allege a link between the acetaminophen in Tylenol and liver damage. This study serves to remind that even something as ubiquitous as acetaminophen may be associated with significant risks,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is offering free Tylenol lawsuit reviews to individuals who may have been harmed by any Tylenol-brand medication.
Tylenol Liver Damage Allegations
According to court documents, more than 120 Tylenol lawsuits have been filed in the U.S. District Court, Eastern District of Pennsylvania on behalf of victims of acetaminophen-induced liver damage that was allegedly caused by a Tylenol-brand over-the-counter medication. Many of these lawsuits further allege that Tylenol users experienced liver damage that resulted in hospitalization, the need for liver transplantation, or death, even when the medication was used in accordance with label directions. The Court has scheduled the litigation’s next Case Management Conference for March 18, 2014. (In Re: Tylenol (Acetaminophen) Marketing, Sales Practices and Products Liability Litigation, MDL No. 2436)
In 2009, the U.S. Food & Drug Administration reported that acetaminophen, the active ingredient in Tylenol-brand medications was the leading cause of acute liver failure in the U.S. between 1998 and 2003.** This past January, new guidelines limiting the amount of acetaminophen in prescription products to 325 mg per tablet went into affect, according to the agency.
Individuals who may have suffered serious liver injuries due to their use of a Tylenol product may be entitled to compensation for their injury-related damages. To learn more about the potential link between Tylenol and liver damage, please visit Bernstein Liebhard LLP’s website. Free, confidential and no-obligation case reviews are available by calling 800-511-5092.
*archpedi.jamanetwork.com/article.aspx?articleid=1833486, JAMA Pediatrics, February 2014
**fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM164897.pdf, FDA, 2009
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP